

Jasbir Sagoo, Ph.D.

Direct Line: 617-439-2394
Fax: 617-310-9994
E-mail: js@nutter.com

February 27, 2002

Assistant Commissioner for Patents Washington, D.C. 20231

Re:

U.S. Patent Application No. 09/996,630

EXPRESSION ANALYSIS OF KIAA NUCLEIC ACIDS AND POLYPEPTIDES USEFUL

IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

Applicant: Kimberly A. Gillis, Ph.D., et al

Docket No: 102729-10

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

- 1. Information Disclosure Statement;
- 2. PTO-1449, Fifty-two (52) references cited therein;
- 3. Return postcard.

Please charge any additional fee to our Deposit Account No. 141449.

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, DC 20231 on:

February 27, 2002

Date

Jasbir Sagoo, Registration No. P-51177

Respectfully submitted,

Jashir Sagoo)

Reg. No: P-51177

Nutter, McClennen & Fish, LLP

One International Place Boston, MA 02110-2699

Agent For Applicants

1081881.1



## HE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant** 

Kimberly A. Gillis, Ph.D., et al.

Application No.: 09/996,630

Filed

: November 28, 2001

Entitled

: EXPRESSION ANALYSIS OF KIAA

NUCLEIC ACIDS AND

POLYPEPTIDES USEFUL IN THE DIAGNOSIS AND TREATMENT OF

PROSTATE CANCER

Docket No.

102729-10

Group Art Unit: 1619

Examiner: Not Yet Assigned

Certi	ficate of Mailing (37 C.F.R. 1.8(a))
	g deposited with the United States Postal Service Post Office as first at Commissionen for Patents, Washington, D.C. 20231 on the date set forth
February 27, 2002	By: Seen
Date of Signature and Mail Deposit	Jasbir Sagoo Reg. No: P-51177

## INFORMATION DISCLOSURE STATEMENT

**Assistant Commissioner for Patents** Washington, DC 20231

## Dear Sir:

Applicant hereby cites for the record in this application the enclosed documents listed on the attached copy of PTO Form 1449. The enclosed Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. Accordingly, Applicant believes that no fee or certification is required.

The Assistant Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 141449.

Respectfully submitted,

NUTTER, MCCLENNEN & FISH, LLP

Date: February 27, 2002

Jasbir Sagoo

Reg. No. P-51177 Agent for Applicants

One International Place Boston, MA 02110-2699

Tel: (617)439-2994 Fax: (617)310-9994

1081899.1

MAR 0 7 2002

•	0 7 2002	of 1995	5, no persons are required to r	U. S. Patent and Tradem	PTO/SB/08A (10-0 roved for use through 10/31/2002.OMB 0651-003 lark Office: U.S. DEPARTMENT OF COMMERC nation unless it contains a valid OMB control number
-402	stitute for form 1449A/PTO				Complete if Known
Oub	30000 101 10101 1440/47 10			Application Number	09/996,630
IN	<b>IFORMATION</b>	I DI	SCLOSURE	Filing Date	November 28, 2001
S	TATEMENT	3Y /	APPLICANT	First Named Inventor	Kimberly A. Gillis, Ph.D., et al.
				Art Unit	1619
	(use as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	102729-10

			U.S. PA	TENT DOCUMENTS	i was a
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevant
Initials*	No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	of Cited Document	Passages or Relevant Figures Appear
	AA	5,030,559	07-09-1991	Nicolson et al.	
	AB	5,118,611	06-02-1992	Smith et al.	The same of the sa
	AC	5,629,007	05-13-1997	Audia et al.	Francis
	AD	5,635,197	06-03-1997	Audia et al.	
	AE	5,674,682	10-07-1997	Croce et al.	- The contract of the contract
	AF	5,688,658	11-18-1997	Diamandis	
	AG	5,723,302	03-03-1998	Diamandis	17.7
	AH	5,763,202	06-09-1998	Horoszewicz	( 3
	Al	5,843,994	12-01-1998	Samid	Can J
	AJ	5,854,206	12-29-1998	Twardzik et al.	1.
	AK	5,856,112	01-05-1999	Marley et al.	
	AL	5,861,248	01-19-1999	Russell et al.	

		FOREI	GN PATENT	DOCUMENTS		$\neg$
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
minais	NO.	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			Figures Appear	T <sup>6</sup>
	BA	WO 97/08318	03-06-1997	Corixa Corporation		
	BB	WO 97/33909	09-18-1997	Corixa Corporation	d to	
	BC	WO 98/37093	08-27-1998	Corixa Corporation		
	BD	WO 98/37418	08-27-1998	Corixa Corporation		$\Box$
	BE	WO 99/18210	04-15-1999	Corixa Corporation		
	BF	WO 99/37811	07-29-1999	UROCOR, Inc.	1	П
	BG	WO 00/04149	01-27-2000	Corixa Corporation		
	BH	WO 00/14234	03-16-2000	UROCOR, Inc.		П
	BI	WO 00/18961	04-06-2000	Millennium Pharmaceuticals,		П
			00.00.0000	Inc.		╂╌
	BJ	EP 0 648 126 B1	02-02-2000	Procyon Biopharma, Inc.		$oldsymbol{\perp}$
	BK	EP 0 698 215 B1	07-15-1998	Nordion International, Inc.		
	BL	EP 0 974 652 A1	01-26-2000	Banyu Pharmaceutical Co., Ltd.		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>				
	CA	Cleutjens, et al., "Two Androgen Response Regions Cooperate in Steroid Hormone Regulated Activity of the Prostate-specific Antigen Promoter," The Journal of Biological Chemistry, Vol. 271, No. 11, March 15, 1996, pp 6379-6388					
	СВ	Henttu, et al., "Androgens Up-Regulate the Human Prostate-Specific Antigen Messenger Ribonucleic Acid (mRNA), but Down-Regulate the Prostatic Acid Phosphatase mRNA in the LNCaP Cell Line," Endocrinology, Vol. 130, No. 2, 1992, pp 772					
	СС	Horoszewicz, et al., "LNCaP Model of Human Prostatic Carcinoma"," Cancer Research, Vol 43, April 1983, pp 1809-1818					

MAR 0 7 2002

of

3

2

Sheet

PTO/SB/08B (19-04)
Approved for use through 10/31/2002.OMB 0651-**po3**1
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMENCE
persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO 09/996,630 Application Number INFORMATION DISCLOSURE November 28, 2001 Filing Date STATEMENT BY APPLICANT Kimberly A. Gillis, Ph.D., et al First Named Inventor 1619 Group Art Unit (use as many sheets as necessary) Not Yet Assigned Examiner Name 102729-10

Attorney Docket Number

Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Whe Passage	olumns, Line e Relevant es or Relevar es Appear	
	AM	5,882,864	03-16-1999	An et al.		. Age	
	AN	5,939,258	08-17-1999	Croce et al.		:	
	AO	5,945,522	08-31-1999	Cohen et al.		F 1	
	AP	5,972,615	10-26-1999	An et al.		1,3	
	AQ	5,976,794	11-02-1999	Katz et al.			
***************************************	AR	5,976,838	11-02-1999	Jacobs et al.			1.5
	AS	6,025,137	02-15-2000	Shyjan		14.	
	AT	6,028,174	02-22-2000	Ullrich et al.			1.1
	AU	6,034,218	03-07-2000	Reed et al.		N.	
	AV	6,051,230	04-18-2000	Thorpe et al.	:		
	AW	6,054,265	04-25-2000	Barney, et al.			
	AX	6,252,058 B1	06-26-2001	Thompson	· ·		11.
	AY	6,261,535 B1	07-17-2001	Thorpe et al.			
	AZ	6,261,766 B1	07-17-2001	Diamandis		1.4.	
	AAA	6,319,891 B1	11-20-2001	Sontheimer et al.			
-							

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CD	Kokontis, et al., "Increased Androgen Receptor Activity and Altered c-myc Expression in Prostate Cancer Cells after Long-Term Androgen Deprivation," Cancer Research, Vol. 54, March 15, 1992, pp 1566-1573	
	CE	Murtha, et al., "Androgen Induction of a Human Prostate-Specific Kallikrein, hKLK2: Characterization of an Androgen Response Element in the 5' Promoter Region of the Gene <sup>†</sup> ," Biochemistry, Vol. 32, 1993, pp 6459-6464	
	CF	Nagase, et al., "Prediction of the Coding Sequences of Unidentified Human Genes. III. The Coding Sequences of 40 New Genes (KIAA0081-KIAA0120) Deduced by Analysis of cDNA Clones from Human Cell Line KG-1," DNA Research, Vol. 2, 1995, pp 37-43, Supplement, pp 51-59	
	CG	Nomura <i>et al.</i> , "Prediction of the Coding Sequences of Unidentified Human Genes. I. The Coding Sequences of 40 New Genes (KIAA0001-KIAA0040) Deduced by Analysis of Randomly Sampled cDNA Clones from Human Immature Myeloid Cell Line KG-1," <i>DNA Research</i> , Vol. 1, 1994, pp 27-35 <i>Virology</i> , Vol. 71, No. 9, September 1997, pp 6973-6981.	
	СН	Nomura et al., "Prediction of the Coding Sequences of Unidentified Human Genes. II. The Coding Sequences of 40 New Genes (KIAA0041-KIAA0080) Deduced by Analysis of cDNA Clones from Human Cell Line KG-1," DNA Research, Vol. 1, 1994, pp 223-229	
	CI	Schuurmans, et al., "Regulation Of Growth Of LNCaP Human Prostate Tumor Cells By Growth Factors And Steroid Hormones," J. Steroid Biochem. Molec. Biol., Vol. 40, No. 1-3, 1991, pp 193-197	
	CJ	Swinnen, et al., "Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocarcinoma cell line LNCaP," Molecular and Cellular Endocrinology, Vol. 104, 1994, pp 153-162	
	CK	Swinnen, et al.,"Androgens Markedly Stimulate the Accumulation of Neutral Lipids in the Human Prostatic Adenocarcinoma Cell Line LNCaP," Endocrinoloy, Vol. 137, No. 10, 1996, pp 4468-4474	

PTO/SB/08B (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
ond to a collection of information unless it contains a valid OMB control number.

Sul	ostitute for form 1449B/PTC		Complete if Known			
			Application Number	09/996,630		
11	<b>VEORMATION</b>	I DISCLOSURE	Filing Date	November 28, 2001		
S	TATEMENT I	BY APPLICANT	First Named Inventor	Kimberly A. Gillis, Ph.D., et al.		
_			Group Art Unit	1619		
	(use as many she	eets as necessary)	Examiner Name	Not Yet Assigned		
Sheet	3	of 3	Attorney Docket Number	102729-10		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	I j			
	CL	Tamayo, et al., "Interpreting patterns of gene expression with self-organizing maps: Methods and application to hematopoietic differentiation," Proc. Natl. Acad. Sci. USA, Vol. 96, March 1999, pp 2907-2912				
	СМ	Ulrix et al., "Androgens Down-Regulate the Expression of the Human Homologue of Paternally Expressed Gene-3 in the Prostatic Adenocarcinoma Cell Line LNCaP," Molecular and Cellular Endocrinology, Vol. 155, 1999, pp 69-76	0/200			

Examiner	1.44		Date	
Signature			Considered	*

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1081906.1

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.





## LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Gavin Bogle is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Wyeth-Ayerst, to prepare and prosecute patent applications wherein the assignee of record of the entire interest is American Home Products Corporation, Wyeth-Ayerst Laboratories, Wyeth-Ayerst International, Inc., Wyeth-Ayerst Research, or Genetics Institute. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Gavin Bogle ceases to lawfully reside in the United States, (ii) Gavin Bogle's employment with Wyeth-Ayerst ceases or is terminated, or (iii) Gavin Bogle ceases to remain or reside in the United States on a TN visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: July 8, 2002

Harry I. Moatz

Director of Enrollment and Discipline